Business Wire

Lightbits Labs Launches LightOS® 2.0 with High Availability

Share

Lightbits Labs, the originator and leader in NVMe™ over TCP (NVMe/TCP) software-defined block storage, today launched LightOS® 2.0, enabling full cloud-native persistent storage integration for Kubernetes with unprecedented scaling and availability via clustering.

With the efficiency and convenience of all-flash arrays and the high performance of direct-attached flash storage, LightOS 2.0 enables independent scaling of compute and storage. This solution maximizes Kubernetes functionality, provides ease of migration and delivers fast recovery times following server failure. LightOS 2.0 provides virtual NVMe volumes, delivering low latency and high performance, while at the same time providing high availability via seamless target-side storage server failover. The result is no interruption in service or forced migration due to a drive or storage node failure.

“Lightbits Labs is the only storage solution in production in the market today that allows data centers to take full advantage of NVMe/TCP,” said Lip-Bu Tan, Lightbits Board Member and Founding Managing Partner of WRVI Capital. “The advancements in LightOS 2.0 will ensure that customers can easily scale their infrastructure, and in-turn their business, without compromising performance, efficiency, or cost.”

LightOS 2.0 leverages a Container Storage Interface (CSI) plugin for Kubernetes to address the growing need for third-party storage support for stateful container storage needs. This has become more important as Kubernetes microservices move from stateless to stateful applications. LightOS 2.0 is ideal for containerized environments like Kubernetes that require large-scale clusters with persistent and durable storage for rapid node migration, workload rebalancing, or recovery from failure without copying data over the network. If any computer node in the network fails, data is moved virtually by pointing it to another container. Taken together, LightOS 2.0 allows for lower TCO via higher capacity utilization as well as increased operational efficiency via decreased downtime and infrastructure flexibility.

“At cloud scale, everything fails. LightOS 2.0 is the industry’s first NVMe/TCP scale-out clustered storage solution – protecting against data loss and avoiding service interruptions at scale in the presence of SSD, server, storage, or network failures,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs. “Now containerized applications can enjoy all of the benefits of disaggregated storage using LightOS CSI plugin for Kubernetes, spinning up persistent storage volumes for containerized workloads just as easily as spinning up another container.”

When installed on commodity servers in large-scale data centers, LightOS 2.0 is automatically optimized for I/O intensive compute clusters, such as Kafka, Cassandra, MySQL, MongoDB, and time series databases. Each storage server in the cluster can support up to 64K namespaces and 16K connections. With LightOS 2.0 providing a highly available and durable storage layer, application teams can focus their efforts on developing new services while LightOS 2.0 takes care of the underlying whole storage platform, guaranteeing the availability of and high-performance access to the data.

“It’s clear that customers want on-demand, high performance, always-available storage no matter where their workloads run. As applications move to the edge, we’re excited about the potential of Lightbits LightOS 2.0 to leverage our rich, interconnected datacenter fabrics, providing local flash-style performance without the operational and reliability issues of server installed drives.” – Zachary Smith, Managing Director for Bare Metal, Equinix

LightOS 2.0 provides the following benefits:

  • Software-defined disaggregated storage for cloud data centers delivering direct-attached NVMe SSD performance and up to a 50% reduction in tail latency
  • Optimized for low-cost QLC flash: Extends write endurance of drives and improves write performance without the need to modify applications
  • Fast container migration via CSI persistent and durable storage
  • Standards-based NVMe/TCP block storage access protocol for application-server-to-storage-server communication
  • LightOS clusters leverage standard NVMe-oF 1.1 multipathing with data protection on the storage target side, providing transparency to the client with fast failover
  • Distributed and durable cluster management with fast failover handling
  • No single point of failure in data and control paths
  • Multiple LightOS clusters can exist in the same cloud data center and clients can use multiple clusters simultaneously
  • Support for Kubernetes v1.13 and v1.15 - v1.18 and later for any volume size, number of volumes or Kubernetes size cluster
  • Rolling upgrades allow for LightOS updates without disruption to storage clients
  • Target-side solution that is easy to deploy at scale, without having to touch the network infrastructure or the clients
  • In cases where Kubernetes is integrated with the OpenStack platform, LightOS 2.0 allows for stateful containers through Kubernetes via CSI, or via a Cinder plugin

“LightOS 2.0 is game changing for the data center. It transforms a rack of x86 servers with NVMe drives into a large high-performance highly redundant storage pool connected to applications servers via NVMe/TCP with Kubernetes integration and high availability. Everything is standard in the solution – TCP protocol on Ethernet, network switches, NICs and drivers – without the need to consider specialized and costly new network infrastructure. Thus LightOS protects current investments and boosts deployments at no risk to deliver new SLA levels for modern application workloads. This is the perfect illustration of the Software-Defined Storage philosophy,” says Philippe Nicolas, Analyst Coldago Research.

To learn more about LightOS 2.0, join our upcoming webinar on June 30th at 10 a.m. PT, “Kubernetes Assimilation: Persistence is Futile.” Josh Goldenhar, VP of Product Marketing, will discuss how you can deploy high performance, low latency block storage in Kubernetes environments and get great performance, increased reliability and lower cost. Register now to save your seat.

Lightbits Labs Resources

About Lightbits Labs™

Lightbits Labs, founded in 2016, is a software-defined storage company that brings hyperscale efficiency and flexibility to everyone. Lightbits’ solution delivers composable, disaggregated NVMe/TCP software-defined storage that performs like local Flash. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that from applications’ perspective is indistinguishable from local SSDs. Lightbits Labs is backed by strategic investors including Dell Technologies Capital, Cisco Investments and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.

Contact information

Alan Ryan / Marianne Dempsey
On behalf of Lightbits Labs
alanryan@rainierco.com / mdempsey@rainierco.com
508-577-6635 or 617-233-8675

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a